JP5802198B2 - 経口投与のための新規の光増感剤製剤 - Google Patents

経口投与のための新規の光増感剤製剤 Download PDF

Info

Publication number
JP5802198B2
JP5802198B2 JP2012508649A JP2012508649A JP5802198B2 JP 5802198 B2 JP5802198 B2 JP 5802198B2 JP 2012508649 A JP2012508649 A JP 2012508649A JP 2012508649 A JP2012508649 A JP 2012508649A JP 5802198 B2 JP5802198 B2 JP 5802198B2
Authority
JP
Japan
Prior art keywords
photosensitizer
oral
time
period
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012508649A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525411A5 (https=
JP2012525411A (ja
Inventor
ファルマー，ゲラルド
ニファンティエフ，ニコライ
アルブレヒト，フォルカー
ノイベルガー，ウォルフガング
シェグルマン，ダイエットリッチ
ゲルハルト，ヴィーラント
ヴィーエ，アルノ
グレーフェ，スザンナ
Original Assignee
セラムオプテック ゲーエムベーハー
セラムオプテック ゲーエムベーハー
バイオリテック リサーチ ゲーエムベーハー
バイオリテック リサーチ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラムオプテック ゲーエムベーハー, セラムオプテック ゲーエムベーハー, バイオリテック リサーチ ゲーエムベーハー, バイオリテック リサーチ ゲーエムベーハー filed Critical セラムオプテック ゲーエムベーハー
Publication of JP2012525411A publication Critical patent/JP2012525411A/ja
Publication of JP2012525411A5 publication Critical patent/JP2012525411A5/ja
Application granted granted Critical
Publication of JP5802198B2 publication Critical patent/JP5802198B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012508649A 2009-04-28 2010-04-28 経口投与のための新規の光増感剤製剤 Expired - Fee Related JP5802198B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17347709P 2009-04-28 2009-04-28
US61/173,477 2009-04-28
PCT/US2010/032780 WO2010129340A2 (en) 2009-04-28 2010-04-28 Novel photosensitizer formulations for oral administration

Publications (3)

Publication Number Publication Date
JP2012525411A JP2012525411A (ja) 2012-10-22
JP2012525411A5 JP2012525411A5 (https=) 2014-01-23
JP5802198B2 true JP5802198B2 (ja) 2015-10-28

Family

ID=43050758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012508649A Expired - Fee Related JP5802198B2 (ja) 2009-04-28 2010-04-28 経口投与のための新規の光増感剤製剤

Country Status (5)

Country Link
US (1) US20120101427A1 (https=)
EP (1) EP2424536A4 (https=)
JP (1) JP5802198B2 (https=)
CN (1) CN102695509A (https=)
WO (1) WO2010129340A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015183346A2 (en) * 2014-01-31 2015-12-03 Washington University Imaging and treatment of pathophysiologic conditions by cerenkov radiation
US9974870B2 (en) 2014-06-09 2018-05-22 Washington University Compositions and methods for treatment and imaging using nanoparticles
US10456375B2 (en) 2014-09-30 2019-10-29 Biolitec Unternehmensbeteiligungs Ii Ag Specifically meso-substituted porphyrins and chlorins for photodynamic therapy
ES3011714T3 (en) 2016-02-26 2025-04-08 Biolitec Holding Gmbh & Co Kg Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy
ES2895851T3 (es) * 2016-04-01 2022-02-22 Trioptotec Gmbh Dispersión de fotosensibilizador y uso de la misma
EP3894421A1 (en) 2018-12-10 2021-10-20 Universität Hamburg Specifically glyco-substituted porphyrins and chlorins for photodynamic therapy
FR3100247B1 (fr) * 2019-09-02 2021-08-06 Centre Nat Rech Scient Dérivé de phénazine et ses utilisations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223494A (en) * 1989-09-25 1993-06-29 The Rockefeller University Orally administered porphyrins to control intestinal iron absorption
US5514669A (en) * 1993-09-29 1996-05-07 Medical College Of Ohio Use of photodynamic therapy to treat prostatic tissue
US6602274B1 (en) * 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
WO2000051638A1 (en) * 1999-02-26 2000-09-08 Qlt Phototherapeutics Inc. Photodynamic therapy in combination with apoptosis inducing factors
AU2001258117A1 (en) * 2000-05-08 2001-11-20 The University Of British Columbia Supports for photosensitizer formulations
US6558653B2 (en) * 2001-09-19 2003-05-06 Scot N. Andersen Methods for treating periodontal disease
CA2466425A1 (en) * 2001-11-09 2003-05-15 Qlt Inc. Photodynamic therapy for the treatment of hair loss
US20040077621A1 (en) * 2002-08-08 2004-04-22 Academia Sinica Antioxidants
US20050049228A1 (en) * 2003-09-02 2005-03-03 Ceramoptec Industries Inc. Antimicrobial photodynamic therapy compound and method of use
RU2406480C2 (ru) * 2005-04-08 2010-12-20 Озфарма Пти Лтд Трансбуккальная система доставки
US20060264423A1 (en) * 2005-05-20 2006-11-23 Bioenvision, Inc. Methylene Blue Therapy of Viral Disease
US20090285766A1 (en) * 2005-06-13 2009-11-19 National University Of Singapore Photosensitising Composition and Uses Thereof
WO2007144048A2 (en) * 2006-06-12 2007-12-21 Dsm Fine Chemicals Austria Nfg Gmbh & Co. Kg Presentation form for the oral administration of phenothiazine dyes, its production and use
US20070299046A1 (en) * 2006-06-26 2007-12-27 Mai Nguyen Brooks Orally available light-independent antineoplastic compounds
WO2008052350A1 (en) * 2006-11-03 2008-05-08 Qlt Inc. Photodynamic therapy for the treatment of hidradenitis suppurativa

Also Published As

Publication number Publication date
EP2424536A4 (en) 2012-10-31
US20120101427A1 (en) 2012-04-26
WO2010129340A2 (en) 2010-11-11
WO2010129340A3 (en) 2011-04-07
CN102695509A (zh) 2012-09-26
EP2424536A2 (en) 2012-03-07
JP2012525411A (ja) 2012-10-22

Similar Documents

Publication Publication Date Title
JP5802198B2 (ja) 経口投与のための新規の光増感剤製剤
Aebisher et al. The use of photodynamic therapy in medical practice
Mosaddad et al. Photodynamic therapy in oral cancer: a narrative review
Zhen et al. Ferritin nanocages to encapsulate and deliver photosensitizers for efficient photodynamic therapy against cancer
JP2731032B2 (ja) 光化学療法による悪性および非悪性病変の検出および治療方法
Bown Photodynamic therapy for photochemists
WO2010129337A3 (en) New oral formulations for tetrapyrrole derivatives
TW200902114A (en) Methods and systems for treating cell proliferation disorders
JP2005507383A (ja) 化合物
JP2003292459A (ja) 熱応答粘膜接着性医薬−担体組成物
CN106109455A (zh) 以5‑氨基乙酰丙酸或其衍生物作为有效成分的抗疟药
Shi et al. Metronomic photodynamic therapy with 5-aminolevulinic acid induces apoptosis and autophagy in human SW837 colorectal cancer cells
JP2015517523A5 (https=)
KR102363327B1 (ko) 5-아미노레불린산 수화염화물을 포함하는 광역학 치료용 조성물
JP2012525411A5 (https=)
Xie et al. Novel carrier-free nanodrug enhances photodynamic effects by blocking the autophagy pathway and synergistically triggers immunogenic cell death for the efficient treatment of breast cancer
Lim et al. The neovessel occlusion efficacy of 151‐hydroxypurpurin‐7‐lactone dimethyl ester induced with photodynamic therapy
TWI834868B (zh) 難治性癌症之預防或治療用之醫藥組合物
WO2010001102A2 (en) Method
CN110022874A (zh) 以tpcs-2a诱导的吉西他滨光化学内在化治疗胆管癌
JP7357386B2 (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
JP2007500227A (ja) 光増感剤及び音増感剤と関連してのニトロキシドの使用方法
JP2022544597A (ja) 創傷治癒及び組織再生特性を有する治療システム、デバイス及び組成物、その使用、並びに対応する方法
F Isaac-Lam et al. Photodynamic therapy applications in cancer, infections and cardiovascular disease
WO2015103447A1 (en) Oral rapamycin nanoparticle preparations and use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140910

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140918

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141009

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141210

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150501

TRDD Decision of grant or rejection written
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150702

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150811

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150828

R150 Certificate of patent or registration of utility model

Ref document number: 5802198

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees